Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
India

How to leverage India: TrialTrove trial starts data, 2010

This article was originally published in Scrip

  • Norman Oxlade

Executive Summary

India's position as a hotbed for industry-sponsored clinical trials is growing in leaps and bounds. The following charts, illustrating Phase II-III trials initiated in the country in 2010, paint a picture of one major emerging market's clinical trials landscape, including top therapy areas, most active trial sponsors and most popular indications. Data provided by TrialTrove.

Table

View full table

Topics

Tags:
India
Latest Headlines

Quick Listen: Scrip's Five Must-Know Things

Avistone Wins China Approval For First C-Met Inhibitor In Glioblastoma

Are Jubilant Pharmova’s US Plant Closure, FDA Observations At Canada Unit A Concern?

X4 Gets First Approval In Ultra-Rare Disorder, Needs Time To Build A Market

See All
UsernamePublicRestriction

Register

SC012784

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By